Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.

Abstract: The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.

Abstract: Needle-less injectors for liquids are known in many different forms which are adapted to different conditions of use. The needle-less injector according to the invention is in the form of a hand-held unit. It includes a locking stressing mechanism, an energy-storing spring (36), a hollow plunger (37) displaceable in a cylinder (38) and a nozzle (39). At its one end, the hollow plunger is provided with a valve body (42). The supply container (44) for the liquid is arranged within the housing. When the locking stressing mechanism is stressed by rotation of the two housing portions (31, 32) relative to each other the hollow plunger (37) is drawn out of the cylinder (38); at the same time the amount of liquid required for an injection is conveyed out of the supply container (44) through the plunger into the pump chamber (43). After the locking stressing mechanism is triggered the amount of liquid is expelled from the pump chamber through the nozzle.

Abstract: Needle-less injectors for liquids are known in many different forms which are adapted to different conditions of use. The needle-less injector according to the invention is in the form of a hand-held unit. It includes a locking stressing mechanism, an energy-storing spring (36), a hollow plunger (37) displaceable in a cylinder (38) and a nozzle (39). At its one end, the hollow plunger is provided with a valve body (42). The supply container (44) for the liquid is arranged within the housing. When the locking stressing mechanism is stressed by rotation of the two housing portions (31, 32) relative to each other the hollow plunger (37) is drawn out of the cylinder (38); at the same time the amount of liquid required for an injection is conveyed out of the supply container (44) through the plunger into the pump chamber (43). After the locking stressing mechanism is triggered the amount of liquid is expelled from the pump chamber through the nozzle.

Abstract: The present invention relates to live PRRS viruses which are attenuated by amino acid mutations in a specific site of the viral protein coded by the open reading frame (ORF) selected from the group of ORF 1a, ORF 1b and/or ORF 2. The invention also pertains to nucleotide sequences coding said viruses, methods of generating such viruses and their use for the preparation of a pharmaceutical composition for the prophylaxis and treatment of PRRS infections.

Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.

Abstract: This invention relates to the use of specifically attenuated live BVD (bovine viral diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.

Abstract: Needle-less injectors for liquids are known in many different forms which are adapted to different conditions of use.

Abstract: The present invention relates to live PRRS viruses which are attenuated by amino acid mutations in a specific site of the viral protein coded by the open reading frame (ORF) selected from the group of ORF 1a, ORF 1b and/or ORF 2. The invention also pertains to nucleotide sequences coding said viruses, methods of generating such viruses and their use for the preparation of a pharmaceutical composition for the prophylaxis and treatment of PRRS infections.

Abstract: This application is concerned with immunogenic polypeptides of pestiviruses, specifically Classical Swine Fever Virus (CVFV), specifically the nonstructural protein p10, more specifically T-cell epitopes from this protein and nucleic acid molecules encoding these polypeptides, and vaccines and diagnostics with these polypeptides or nucleic acid molecules.